MaxCyte, Inc. (MXCT) stock

MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3065% below fair value

$1.10−0.03 (-2.65%)

Close on Nov 11, 2026Market cap $113.53MP/E –Yield –

MaxCyte price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

MaxCyte's price to sales ratio was 3.8× on Nov 11, 2026, against 5.5× a year earlier. Over the last 5 years it ranged from 2.3× to 31.7×, with a median of 9.6×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	3.8×	−1.0
2025	Dec 31, 2025	4.8×	−4.8
2024	Dec 31, 2024	9.6×	−3.2
2023	Dec 29, 2023	12.8×	−0.5
2022	Dec 30, 2022	13.3×	−18.5
2021	Dec 31, 2021	31.7×	–